drugset / Trial / NCT01221870
Tesetaxel as First-line Therapy for Metastatic Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The intravenously administered taxane, paclitaxel, is one of the most commonly employed agents for the treatment of both localized and advanced breast cancer. Tesetaxel is an orally administered taxane that is in development as first- and second-line treatment for patients with advanced cancers. This study is being undertaken to determine the efficacy and safety of tesetaxel administered as first-line therapy to patients with metastatic breast cancer.
Timeline
- Start
- 2010-11
- Primary completion
- 2012-10
- Completion
- 2013-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tesetaxel | Small molecule | 15 mg/m2 | Oral |
| Subject | Tesetaxel | Small molecule | 27 mg/m2 | Oral |